{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [
    "2 Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA",
    "2University of Virginia, Charlottesville, VA, USA",
    "4University of Illinois, Chicago, IL, USA",
    "5Indiana University, Indianapolis, IN, USA",
    "7Duke University Medical Center, Durham, NC, USA",
    "Grid Therapeutics, LLC, Chapel Hill, NC, USA"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Hirva Mamdani"
    },
    {
      "affs": [
        1
      ],
      "name": "Ryan Gentzler"
    },
    {
      "affs": [
        2
      ],
      "name": "Frank Weinberg"
    },
    {
      "affs": [
        3
      ],
      "name": "Gregory Durm"
    },
    {
      "affs": [
        4
      ],
      "name": "James Herndon"
    },
    {
      "affs": [
        5
      ],
      "name": "Edward F Patz"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e0czmrky9wek0.bib",
  "cited_by": 0,
  "doi": "10.1136/jitc-2026-sitc2026.1193",
  "fulltext_url": null,
  "id": "e0czmrky9wek0",
  "issns": [
    "2051-1426"
  ],
  "landing_url": "https://doi.org/10.1136/jitc-2026-sitc2026.1193",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7225422109",
  "pdf_url": "https://jitc.bmj.com/content/14/Suppl_3/A1409.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-08",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/e0czmrky9wek0.ris",
  "sources": [
    {
      "first_seen": "2026-11-08T14:21:05Z",
      "native_id": "900ddc150dcd4e05aba62d392fa59415",
      "source": "doaj",
      "url": "https://doi.org/10.1136/jitc-2026-sitc2026.1193"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "1193 Analysis of a Phase II trial with GT103 in combination with pembrolizumab in refractory, advanced stage non–small cell lung cancer",
  "title_text": "1193 Analysis of a Phase II trial with GT103 in combination with pembrolizumab in refractory, advanced stage non–small cell lung cancer",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T14:21:24Z",
  "url": "https://research.draconitic.com/paper/e0czmrky9wek0",
  "venue": "Journal for ImmunoTherapy of Cancer",
  "versions": []
}